Cellectar Biosciences, Inc. Share Price & Technical Analysis
CLRB · $3.20 (+0.95%)
Healthcare / Biotechnology
$3.20
+0.95%
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with rel…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
19% return in May, 0% avg return in past 3 year May month.
3% return in 2026, -49% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | 3% | -22% | -4% | 19% | – | – | – | – | – | – | – | 3% |
| 25 | -19% | 16% | 7% | -22% | 0% | -9% | -9% | 0% | 17% | -38% | 6% | -17% | -69% |
| 24 | 35% | -2% | 0% | -24% | 0% | -19% | -14% | 2% | -1% | -4% | -22% | -81% | -130% |
| 23 | -9% | 7% | -6% | 5% | 1% | 20% | -1% | -11% | 43% | -12% | 2% | 12% | 52% |
| 22 | -17% | -15% | 38% | -22% | -23% | -2% | -2% | 40% | -37% | -39% | -11% | -13% | -104% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$23.45M
P/E ratio
—
52W high
$20.70
52W low
$2.43
Volume
1,45,595
Beta
0.43
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cellectar Biosciences, Inc. share price today?
- Cellectar Biosciences, Inc. (CLRB) last traded around $3.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CLRB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CLRB. Download the app for real-time alerts.
- How can I analyze Cellectar Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.